MSTO‐211H cells, which express lower levels of PTGFRN, were treated with 8C7‐ADC at 1 and 4 mg/kg, resulting in a dose‐dependent tumour inhibition of 32% and 63%, respectively (Figure 4C). Here, PTGFRN is linked to neoplasm.